Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions ...

| Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...